ACRS missed EPS expectations by 353.12%
Mar 13, 2025, 10:32 PM
0.00%
What does ACRS do
Aclaris Therapeutics, a biopharmaceutical company based in Wayne, Pennsylvania, focuses on developing novel drugs for dermatology and immunology, with key candidates including ATI-1777 and Zunsemetinib. Founded in 2015, it employs 91 staff and utilizes its KINect platform for drug discovery.
Aclaris Therapeutics (ACRS) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Aclaris Therapeutics's actual EPS was -$1.01, missing the estimate of -$0.22 per share, resulting in a -353.12% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.